Effectiveness of mass dengue vaccination with CYD-TDV (Dengvaxia®) in the state of Paraná, Brazil: integrating case-cohort and case-control designsResearch in context

Summary: Background: CYD-TDV (Dengvaxia®) was the first dengue vaccine approved, launched in Brazil in 2015 for individuals aged 9–44 years. We aimed to estimate the effectiveness of CYD-TDV in preventing symptomatic dengue cases during a campaign targeting individuals aged 15–27 years in selected...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Fredi Alexander Diaz-Quijano, Denise Siqueira de Carvalho, Sonia Mara Raboni, Silvia Emiko Shimakura, Angela Maron de Mello, Magda Clara Vieira da Costa-Ribeiro, Lineu Silva, Marilene da Cruz Magalhães Buffon, Eliane Mara Cesario Pereira Maluf, Gabriel Graeff, Gustavo Almeida, Clara Preto, Karin Regina Luhm
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2024-07-01
Edice:	The Lancet Regional Health. Americas
Témata:	Dengue Brazil Vaccine effectiveness CYD-TDV Public health surveillance
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2667193X24001042
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!